首页 > 最新文献

Lancet Microbe最新文献

英文 中文
Ecological and evolutionary perspectives advance understanding of mycobacterial diseases 生态学和进化论视角加深了人们对分枝杆菌疾病的了解。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.1016/S2666-5247(24)00138-1
Christine Chevillon PhD , Benoît de Thoisy PhD , Alex W Rakestraw MSc , Kayla M Fast MSc , Jennifer L Pechal PhD , Sophie Picq PhD , Prof Loïc Epelboin MD PhD , Paul Le Turnier MD , Magdalene Dogbe MSc , Heather R Jordan PhD , Michael W Sandel PhD , Prof Mark Eric Benbow PhD , Prof Jean-François Guégan PhD
Predicting the outbreak of infectious diseases and designing appropriate preventive health actions require interdisciplinary research into the processes that drive exposure to and transmission of disease agents. In the case of mycobacterial diseases, the epidemiological understanding of the scientific community hitherto was based on the clinical studies of infections in vertebrates. To evaluate the information gained by comprehensively accounting for the ecological and evolutionary constraints, we conducted literature searches assessing the role of mycobacteria interactions with non-vertebrate species in the origin of their pathogenicity and variations in disease risk. The reviewed literature challenges the current theory of person-to-person transmission for several mycobacterial infections. Furthermore, the findings suggest that diverse non-vertebrate organisms influence virulence, mediate transmission, and contribute to pathogen abundance in relation to vertebrate exposure. We advocate that an ecological and evolutionary framework provides novel insights to support a more comprehensive understanding of the prevention and management of diseases in vertebrates.
要预测传染病的爆发并设计适当的预防保健行动,就必须对疾病病原体的接触和传播过程进行跨学科研究。就分枝杆菌疾病而言,迄今为止科学界对流行病学的理解都是基于对脊椎动物感染的临床研究。为了评估通过全面考虑生态和进化限制因素所获得的信息,我们进行了文献检索,评估分枝杆菌与非脊椎动物物种的相互作用在其致病性起源和疾病风险变化中所起的作用。所查阅的文献对目前几种分枝杆菌感染的人际传播理论提出了质疑。此外,研究结果表明,不同的非脊椎动物会影响致病性、介导传播,并在脊椎动物接触病原体时促成病原体的大量存在。我们认为,生态和进化框架提供了新的见解,有助于更全面地了解脊椎动物疾病的预防和管理。
{"title":"Ecological and evolutionary perspectives advance understanding of mycobacterial diseases","authors":"Christine Chevillon PhD ,&nbsp;Benoît de Thoisy PhD ,&nbsp;Alex W Rakestraw MSc ,&nbsp;Kayla M Fast MSc ,&nbsp;Jennifer L Pechal PhD ,&nbsp;Sophie Picq PhD ,&nbsp;Prof Loïc Epelboin MD PhD ,&nbsp;Paul Le Turnier MD ,&nbsp;Magdalene Dogbe MSc ,&nbsp;Heather R Jordan PhD ,&nbsp;Michael W Sandel PhD ,&nbsp;Prof Mark Eric Benbow PhD ,&nbsp;Prof Jean-François Guégan PhD","doi":"10.1016/S2666-5247(24)00138-1","DOIUrl":"10.1016/S2666-5247(24)00138-1","url":null,"abstract":"<div><div>Predicting the outbreak of infectious diseases and designing appropriate preventive health actions require interdisciplinary research into the processes that drive exposure to and transmission of disease agents. In the case of mycobacterial diseases, the epidemiological understanding of the scientific community hitherto was based on the clinical studies of infections in vertebrates. To evaluate the information gained by comprehensively accounting for the ecological and evolutionary constraints, we conducted literature searches assessing the role of mycobacteria interactions with non-vertebrate species in the origin of their pathogenicity and variations in disease risk. The reviewed literature challenges the current theory of person-to-person transmission for several mycobacterial infections. Furthermore, the findings suggest that diverse non-vertebrate organisms influence virulence, mediate transmission, and contribute to pathogen abundance in relation to vertebrate exposure. We advocate that an ecological and evolutionary framework provides novel insights to support a more comprehensive understanding of the prevention and management of diseases in vertebrates.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"5 11","pages":"Article 100906"},"PeriodicalIF":20.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141907971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial 预防埃博拉病毒疾病的 rVSVΔG-ZEBOV-GP 疫苗延迟加强剂量的安全性和免疫原性:一项多中心、开放标签、2 期随机对照试验。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.1016/S2666-5247(24)00163-0
Richard T Davey Jr. MD , Gary L Collins MS , Nadine Rouphael MD , Guillaume Poliquin MD , Rosemary McConnell RN , Gabrielle Grubbs BS , Susan L Moir PhD , Joanne M Langley MD , Marc Teitelbaum MD , Angela L Hewlett MD , Prof Susan L F McLellan MD , Nahid Bhadelia MD , Vanessa N Raabe MD , Prof Mark J Mulligan MD , Irina Maljkovic Berry PhD , Bonnie Dighero-Kemp BSc , Jonathan R Kurtz PhD , Lisa E Hensley PhD , Nelson C E Dozier MS , Lindsay C B Marron MS , Prof James D Neaton PhD
<div><h3>Background</h3><div>rVSVΔG-ZEBOV-GP is the first approved vaccine with clinical efficacy against Ebola virus disease. Although a seroprotective threshold has not been defined for those at occupational risk of exposure, the current vaccine strategy is to attain a sustained high level of antibody titres. The aim of this trial was to explore the effects of delayed boosting upon both the height and duration of antibody titres following primary immunisation.</div></div><div><h3>Methods</h3><div>In this open-label phase 2 randomised controlled trial, we compared antibody titres at month 36 in participants who had received a homologous booster dose at month 18 following primary immunisation with those who had received no booster. From Oct 25, 2016, to Jan 29, 2020, healthy adults aged 18 years or older deemed at occupational risk of exposure to Ebola virus due to laboratory work, clinical duties, or travel to an active endemic region were recruited from four hospital clinics in the USA and one hospital clinic in Canada and received primary vaccination with 2×10<sup>7</sup> plaque-forming unit per mL of VSVΔG-ZEBOV-GP. 18 months later, individuals who consented and were still eligible were randomly assigned 1:1 to receive either a homologous booster dose or no booster. Study visits for safety and serial blood collections for antibody titres were done on enrolled participants at months 0, 1, 3, 6, 12, 18, 19, 24, 30, and 36. Through July, 2021, a web-based application was used for randomisation, including assignments with schedules for each of the five sites using mixed permuted blocks. The trial was not masked to participants or site staff. The primary endpoint was a comparison of geometric mean titres (GMTs) of anti-Ebola virus glycoprotein IgG antibody at month 36 (ie, 18 months after randomisation) for all randomly assigned participants who completed the 36 months of follow-up (primary analysis cohort). Investigators were aware of antibody titres from baseline (enrolment) through month 18 but were masked to summary data by randomisation group after month 18. This study is registered with <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (<span><span>NCT02788227</span><svg><path></path></svg></span>).</div></div><div><h3>Findings</h3><div>Of the 248 participants who enrolled and received their primary immunisation, 114 proceeded to the randomisation step at month 18. The two randomisation groups were balanced: 57 participants (24 [42%] of whom were female; median age was 42 years [IQR 35–50]) were randomly assigned to the booster group and 57 (24 [42%] of whom were female; median age was 42 years [IQR 36–51]) to the no-booster group. Of those randomly assigned, 92 participants (45 in the booster group and 47 in the no-booster group) completed 36 months of follow-up. At 18 months after primary immunisation, GMTs in the no-booster group increased from a baseline of 10 ELISA units (EU)/mL (95% CI 7–14) to 1451 EU/mL (1118–1882)
背景:rVSVΔG-ZEBOV-GP 是首个获批的具有临床疗效的埃博拉病毒病疫苗。虽然尚未确定职业暴露风险人群的血清保护阈值,但目前的疫苗策略是获得持续的高抗体滴度。本试验的目的是探索延迟强化对初次免疫后抗体滴度的高度和持续时间的影响:在这项开放标签的 2 期随机对照试验中,我们比较了在初次免疫后第 18 个月接受过同源强化剂的参与者与未接受强化剂的参与者在第 36 个月时的抗体滴度。从 2016 年 10 月 25 日至 2020 年 1 月 29 日,我们从美国的四家医院诊所和加拿大的一家医院诊所招募了因实验室工作、临床职责或前往活跃的流行地区而被认为有接触埃博拉病毒职业风险的 18 岁或以上健康成年人,他们接受了每毫升 2×107 个斑块形成单位的 VSVΔG-ZEBOV-GP 初次接种。18 个月后,同意接种且仍符合接种条件的患者按 1:1 的比例被随机分配到接受同种强化免疫或不接受强化免疫。在第 0、1、3、6、12、18、19、24、30 和 36 个月,对入选者进行安全性考察和连续采血检测抗体滴度。到 2021 年 7 月,使用基于网络的应用程序进行随机分配,包括使用混合排列区块为五个地点的每个地点分配时间表。试验不对参与者或试验点工作人员进行蒙蔽。主要终点是比较所有完成36个月随访的随机分配参与者(主要分析队列)在第36个月(即随机分配后18个月)时抗埃博拉病毒糖蛋白IgG抗体的几何平均滴度(GMT)。研究人员了解从基线(入组)到第 18 个月的抗体滴度,但在第 18 个月后,研究人员将被屏蔽,无法获得随机分组的汇总数据。该研究已在 ClinicalTrials.gov (NCT02788227) 上注册:结果:在 248 名注册并接受初次免疫接种的参与者中,有 114 人在第 18 个月时进入随机分组步骤。两个随机分组是平衡的:57名参与者(其中24人[42%]为女性;年龄中位数为42岁[IQR为35-50岁])被随机分配到加强组,57名参与者(其中24人[42%]为女性;年龄中位数为42岁[IQR为36-51岁])被随机分配到不加强组。在随机分配的参与者中,有 92 人(强化免疫组 45 人,无强化免疫组 47 人)完成了 36 个月的随访。初次免疫接种后18个月,无强化免疫组的GMT值从基线的10个ELISA单位(EU)/毫升(95% CI 7-14)升至1451个EU/毫升(1118-1882);强化免疫组的GMT值从9个EU/毫升(6-16)升至1769个EU/毫升(1348-2321)。第 19 个月时,增强组的 GMT 为 31 408 EU/mL(23 181-42 554),无增强组为 1406 EU/mL(1078-1833);第 36 个月时,增强组的 GMT 为 10 146 EU/mL(7960-12 933),无增强组为 1240 EU/mL(984-1563)。因此,在注射加强剂 1 个月后,加强剂组与未注射加强剂组的抗体滴度几何平均比(GMR)增加了近 21 倍(GMR 20-6;95% CI 18-2-23-0;p解释:加强剂组与未注射加强剂组的抗体滴度几何平均比(GMR)增加了近 21 倍(GMR 20-6;95% CI 18-2-23-0):rVSVΔG-ZEBOV-GP强化剂推迟到第18个月使用,除了没有新的安全性问题外,与早期评估短期强化剂的试验形成鲜明对比的是,在至少18个月内,GMT仍比无强化剂组GMT高出数倍。这些发现可能会对确定加强剂量的最佳时机产生影响,以作为埃博拉病毒持续暴露风险人群的暴露前预防措施:美国国立卫生研究院国立过敏与传染病研究所校内研究部和临床研究部、加拿大公共卫生署加拿大免疫研究网络、加拿大卫生研究院和美国国防威胁削减局。
{"title":"Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial","authors":"Richard T Davey Jr. MD ,&nbsp;Gary L Collins MS ,&nbsp;Nadine Rouphael MD ,&nbsp;Guillaume Poliquin MD ,&nbsp;Rosemary McConnell RN ,&nbsp;Gabrielle Grubbs BS ,&nbsp;Susan L Moir PhD ,&nbsp;Joanne M Langley MD ,&nbsp;Marc Teitelbaum MD ,&nbsp;Angela L Hewlett MD ,&nbsp;Prof Susan L F McLellan MD ,&nbsp;Nahid Bhadelia MD ,&nbsp;Vanessa N Raabe MD ,&nbsp;Prof Mark J Mulligan MD ,&nbsp;Irina Maljkovic Berry PhD ,&nbsp;Bonnie Dighero-Kemp BSc ,&nbsp;Jonathan R Kurtz PhD ,&nbsp;Lisa E Hensley PhD ,&nbsp;Nelson C E Dozier MS ,&nbsp;Lindsay C B Marron MS ,&nbsp;Prof James D Neaton PhD","doi":"10.1016/S2666-5247(24)00163-0","DOIUrl":"10.1016/S2666-5247(24)00163-0","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;rVSVΔG-ZEBOV-GP is the first approved vaccine with clinical efficacy against Ebola virus disease. Although a seroprotective threshold has not been defined for those at occupational risk of exposure, the current vaccine strategy is to attain a sustained high level of antibody titres. The aim of this trial was to explore the effects of delayed boosting upon both the height and duration of antibody titres following primary immunisation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this open-label phase 2 randomised controlled trial, we compared antibody titres at month 36 in participants who had received a homologous booster dose at month 18 following primary immunisation with those who had received no booster. From Oct 25, 2016, to Jan 29, 2020, healthy adults aged 18 years or older deemed at occupational risk of exposure to Ebola virus due to laboratory work, clinical duties, or travel to an active endemic region were recruited from four hospital clinics in the USA and one hospital clinic in Canada and received primary vaccination with 2×10&lt;sup&gt;7&lt;/sup&gt; plaque-forming unit per mL of VSVΔG-ZEBOV-GP. 18 months later, individuals who consented and were still eligible were randomly assigned 1:1 to receive either a homologous booster dose or no booster. Study visits for safety and serial blood collections for antibody titres were done on enrolled participants at months 0, 1, 3, 6, 12, 18, 19, 24, 30, and 36. Through July, 2021, a web-based application was used for randomisation, including assignments with schedules for each of the five sites using mixed permuted blocks. The trial was not masked to participants or site staff. The primary endpoint was a comparison of geometric mean titres (GMTs) of anti-Ebola virus glycoprotein IgG antibody at month 36 (ie, 18 months after randomisation) for all randomly assigned participants who completed the 36 months of follow-up (primary analysis cohort). Investigators were aware of antibody titres from baseline (enrolment) through month 18 but were masked to summary data by randomisation group after month 18. This study is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT02788227&lt;/span&gt;&lt;svg&gt;&lt;path&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Of the 248 participants who enrolled and received their primary immunisation, 114 proceeded to the randomisation step at month 18. The two randomisation groups were balanced: 57 participants (24 [42%] of whom were female; median age was 42 years [IQR 35–50]) were randomly assigned to the booster group and 57 (24 [42%] of whom were female; median age was 42 years [IQR 36–51]) to the no-booster group. Of those randomly assigned, 92 participants (45 in the booster group and 47 in the no-booster group) completed 36 months of follow-up. At 18 months after primary immunisation, GMTs in the no-booster group increased from a baseline of 10 ELISA units (EU)/mL (95% CI 7–14) to 1451 EU/mL (1118–1882)","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"5 11","pages":"Article 100923"},"PeriodicalIF":20.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis 中国结核分枝杆菌对 12 种药物产生耐药性的基因突变目录:基因组分析。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.1016/S2666-5247(24)00131-9
Shaojun Pei PhD , Zexuan Song MS , Wei Yang PhD , Wencong He PhD , Xichao Ou MS , Bing Zhao MS , Ping He MS , Yang Zhou MS , Hui Xia PhD , Shengfen Wang PhD , Prof Zhongwei Jia PhD , Timothy M Walker DPhil , Prof Yanlin Zhao PhD
<div><h3>Background</h3><div>WHO issued the first edition catalogue of <em>Mycobacterium tuberculosis</em> complex (MTBC) mutations associated with drug resistance in 2021. However, country-specific issues might lead to arising complex and additional drug-resistant mutations. We aimed to fully reflect the characteristics of drug resistance mutations in China.</div></div><div><h3>Methods</h3><div>We analysed MTBC isolates from the nationwide drug-resistant tuberculosis surveillance with 70 counties in 31 provinces, municipalities, and autonomous regions in China. Three types of MYCOTB plates were used to perform drug susceptibility testing for 12 antibiotics (rifampicin, isoniazid, ethambutol, levofloxacin, moxifloxacin, amikacin, kanamycin, ethionamide, clofazimine, linezolid, delamanid, and bedaquiline). Mutations were divided into five groups according to their odds ratios, positive predictive values, false discovery rate-corrected p values, and 95% CIs: (1) associated with resistance; (2) associated with resistance—interim; (3) uncertain significance; (4) not associated with resistance—interim; and (5) not associated with resistance. The Wilcoxon rank-sum and Kruskal–Wallis tests were used to quantify the association between mutations and minimum inhibitory concentrations (MICs). Our dataset was compared with the first edition of the WHO catalogue.</div></div><div><h3>Findings</h3><div>We analysed 10 146 MTBC isolates, of which 9071 (89·4%) isolates were included in the final analysis. 744 (8·2%) isolates were resistant to rifampicin and 1339 (14·8%) to isoniazid. 208 (1·9%) of 11 065 mutations were classified as associated with resistance or associated with resistance—interim. 33 (97·1%) of 34 mutations in group 1 and 92 (52·9%) of 174 in group 2 also appeared in groups 1 or 2 of the WHO catalogue. Of 81 indel mutations in group 2, 15 (18·5%) were in the WHO catalogue. The newly discovered mutation <em>gyrA</em>_Ala288Asp was associated with levofloxacin resistance. MIC values for rifampicin, isoniazid, moxifloxacin, and levofloxacin corresponding to resistance mutations in group 1 were significantly different (p<0·0001), and 12 high-level resistance mutations were detected. 61 mutations in group 3 occurred as solo in at least five phenotypically susceptible isolates, but with MIC values moderately higher than other susceptible isolates. Among 945 phenotypically resistant but genotypically susceptible isolates, 433 (45·8%) were mutated for at least one efflux pump gene.</div></div><div><h3>Interpretation</h3><div>Our analysis reflects the complexity of drug resistance mutations in China and suggests that indel mutations, efflux pump genes, protein structure, and MICs should be fully considered in the WHO catalogue, especially in countries with a high tuberculosis burden.</div></div><div><h3>Funding</h3><div>National Key Research and Development Program of China and the Science and Technology Major Project of Tibetan Autonomous Region of Ch
背景:世卫组织于 2021 年发布了第一版与耐药性相关的结核分枝杆菌(MTBC)突变目录。然而,各国的具体问题可能会导致产生复杂和额外的耐药性变异。我们旨在全面反映中国耐药突变的特点:我们分析了来自中国 31 个省、市、自治区 70 个县的全国耐药结核病监测的 MTBC 分离物。使用三种类型的 MYCOTB 平板对 12 种抗生素(利福平、异烟肼、乙胺丁醇、左氧氟沙星、莫西沙星、阿米卡星、卡那霉素、乙琥胺、氯法齐明、利奈唑胺、地拉米诺和贝达喹啉)进行药敏试验。根据突变的几率、阳性预测值、假发现率校正 p 值和 95% CI,将突变分为五组:(1) 与耐药性相关;(2) 与耐药性-中期相关;(3) 意义不确定;(4) 与耐药性-中期无关;(5) 与耐药性无关。Wilcoxon 秩和检验和 Kruskal-Wallis 检验用于量化突变与最低抑菌浓度 (MIC) 之间的关联。我们的数据集与第一版世界卫生组织目录进行了比较:我们分析了 10 146 个 MTBC 分离物,其中 9071 个(89-4%)分离物被纳入最终分析。744个(8-2%)分离株对利福平耐药,1339个(14-8%)对异烟肼耐药。在 11 065 个突变中,有 208 个(1-9%)被归类为与耐药性相关或与耐药性初步相关。第 1 组的 34 个突变中有 33 个(97-1%)和第 2 组的 174 个突变中有 92 个(52-9%)也出现在世界卫生组织目录的第 1 组或第 2 组中。在第 2 组的 81 个 indel 突变中,有 15 个(18-5%)出现在 WHO 目录中。新发现的突变 gyrA_Ala288Asp 与左氧氟沙星耐药性有关。与第 1 组耐药性突变相对应的利福平、异烟肼、莫西沙星和左氧氟沙星的 MIC 值有显著差异(p解释:我们的分析反映了中国耐药性突变的复杂性,并建议在世界卫生组织的目录中充分考虑吲哚突变、外排泵基因、蛋白结构和MICs,尤其是在结核病负担较重的国家:国家重点研发计划、西藏自治区科技重大专项。
{"title":"The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis","authors":"Shaojun Pei PhD ,&nbsp;Zexuan Song MS ,&nbsp;Wei Yang PhD ,&nbsp;Wencong He PhD ,&nbsp;Xichao Ou MS ,&nbsp;Bing Zhao MS ,&nbsp;Ping He MS ,&nbsp;Yang Zhou MS ,&nbsp;Hui Xia PhD ,&nbsp;Shengfen Wang PhD ,&nbsp;Prof Zhongwei Jia PhD ,&nbsp;Timothy M Walker DPhil ,&nbsp;Prof Yanlin Zhao PhD","doi":"10.1016/S2666-5247(24)00131-9","DOIUrl":"10.1016/S2666-5247(24)00131-9","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;WHO issued the first edition catalogue of &lt;em&gt;Mycobacterium tuberculosis&lt;/em&gt; complex (MTBC) mutations associated with drug resistance in 2021. However, country-specific issues might lead to arising complex and additional drug-resistant mutations. We aimed to fully reflect the characteristics of drug resistance mutations in China.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We analysed MTBC isolates from the nationwide drug-resistant tuberculosis surveillance with 70 counties in 31 provinces, municipalities, and autonomous regions in China. Three types of MYCOTB plates were used to perform drug susceptibility testing for 12 antibiotics (rifampicin, isoniazid, ethambutol, levofloxacin, moxifloxacin, amikacin, kanamycin, ethionamide, clofazimine, linezolid, delamanid, and bedaquiline). Mutations were divided into five groups according to their odds ratios, positive predictive values, false discovery rate-corrected p values, and 95% CIs: (1) associated with resistance; (2) associated with resistance—interim; (3) uncertain significance; (4) not associated with resistance—interim; and (5) not associated with resistance. The Wilcoxon rank-sum and Kruskal–Wallis tests were used to quantify the association between mutations and minimum inhibitory concentrations (MICs). Our dataset was compared with the first edition of the WHO catalogue.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;We analysed 10 146 MTBC isolates, of which 9071 (89·4%) isolates were included in the final analysis. 744 (8·2%) isolates were resistant to rifampicin and 1339 (14·8%) to isoniazid. 208 (1·9%) of 11 065 mutations were classified as associated with resistance or associated with resistance—interim. 33 (97·1%) of 34 mutations in group 1 and 92 (52·9%) of 174 in group 2 also appeared in groups 1 or 2 of the WHO catalogue. Of 81 indel mutations in group 2, 15 (18·5%) were in the WHO catalogue. The newly discovered mutation &lt;em&gt;gyrA&lt;/em&gt;_Ala288Asp was associated with levofloxacin resistance. MIC values for rifampicin, isoniazid, moxifloxacin, and levofloxacin corresponding to resistance mutations in group 1 were significantly different (p&lt;0·0001), and 12 high-level resistance mutations were detected. 61 mutations in group 3 occurred as solo in at least five phenotypically susceptible isolates, but with MIC values moderately higher than other susceptible isolates. Among 945 phenotypically resistant but genotypically susceptible isolates, 433 (45·8%) were mutated for at least one efflux pump gene.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;div&gt;Our analysis reflects the complexity of drug resistance mutations in China and suggests that indel mutations, efflux pump genes, protein structure, and MICs should be fully considered in the WHO catalogue, especially in countries with a high tuberculosis burden.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;div&gt;National Key Research and Development Program of China and the Science and Technology Major Project of Tibetan Autonomous Region of Ch","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"5 11","pages":"Article 100899"},"PeriodicalIF":20.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring uncatalogued genetic variation in antimicrobial resistance gene families in Escherichia coli: an observational analysis 探索大肠杆菌抗菌药耐药性基因家族中未编入目录的遗传变异:观察分析。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-11-01 DOI: 10.1016/S2666-5247(24)00152-6
Samuel Lipworth DPhil , Prof Derrick Crook FRCP , Prof A Sarah Walker PhD , Prof Tim Peto FRCP , Prof Nicole Stoesser DPhil
<div><h3>Background</h3><div>Antimicrobial resistance (AMR) in <em>Escherichia coli</em> is a global problem associated with substantial morbidity and mortality. AMR-associated genes are typically annotated based on similarity to variants in a curated reference database, with the implicit assumption that uncatalogued genetic variation within these is phenotypically unimportant. In this study, we evaluated the performance of the AMRFinder tool and, subsequently, the potential for discovering new AMR-associated gene families and characterising variation within existing ones to improve genotype-to-susceptibility phenotype predictions in <em>E coli</em>.</div></div><div><h3>Methods</h3><div>In this cross-sectional study of international genome sequence data, we assembled a global dataset of 9001 <em>E coli</em> sequences from five publicly available data collections predominantly deriving from human bloodstream infections from: Norway, Oxfordshire (UK), Thailand, the UK, and Sweden. 8555 of these sequences had linked antibiotic susceptibility data. Raw reads were assembled using Shovill and AMR genes (relevant to amoxicillin–clavulanic acid, ampicillin, ceftriaxone, ciprofloxacin, gentamicin, piperacillin–tazobactam, and trimethoprim) extracted using the National Center for Biotechnology Information AMRFinder tool (using both default and strict [100%] coverage and identity filters). We assessed the predictive value of the presence of these genes for predicting resistance or susceptibility against US Food and Drug Administration thresholds for major and very major errors. Mash was used to calculate the similarity between extracted genes using Jaccard distances. We empirically reclustered extracted gene sequences into AMR-associated gene families (≥70% match) and antibiotic-resistance genes (ARGs; 100% match) and categorised these according to their frequency in the dataset. Accumulation curves were simulated and correlations between gene frequency in the Oxfordshire and other datasets calculated using the Spearman coefficient. Firth regression was used to model the association between the presence of <em>bla</em><sub>TEM-1</sub> variants and amoxicillin–clavulanic acid or piperacillin–tazobactam resistance, adjusted for the presence of other relevant ARGs.</div></div><div><h3>Findings</h3><div>The performance of the AMRFinder database for genotype-to-phenotype predictions using strict 100% identity and coverage thresholds did not meet US Food and Drug Administration thresholds for any of the seven antibiotics evaluated. Relaxing filters to default settings improved sensitivity with a specificity cost. For all antibiotics, most explainable resistance was associated with the presence of a small number of genes. There was a proportion of resistance that could not be explained by known ARGs; this ranged from 75·1% for amoxicillin–clavulanic acid to 3·4% for ciprofloxacin. Only 18 199 (51·5%) of the 35 343 ARGs detected had a 100% identity and coverage mat
背景:大肠埃希菌的抗菌药耐药性(AMR)是一个全球性问题,与严重的发病率和死亡率有关。AMR相关基因的注释通常基于与参考数据库中的变异的相似性,隐含的假设是这些基因中未编入数据库的遗传变异在表型上并不重要。在这项研究中,我们评估了 AMRFinder 工具的性能,并随后评估了发现新的 AMR 相关基因家族和描述现有基因家族中变异的潜力,以改进大肠杆菌中基因型到易感性表型的预测:在这项国际基因组序列数据横断面研究中,我们从五个公开数据集中收集了 9001 个大肠杆菌序列,这些数据主要来自挪威、牛津郡(英国)、泰国、英国和瑞典的人类血液感染。其中 8555 个序列有相关的抗生素敏感性数据。使用 Shovill 对原始读数进行组装,并使用美国国家生物技术信息中心 AMRFinder 工具提取 AMR 基因(与阿莫西林-克拉维酸、氨苄西林、头孢曲松、环丙沙星、庆大霉素、哌拉西林-他唑巴坦和三甲氧苄青霉素相关)(使用默认和严格 [100%] 覆盖率和同一性过滤器)。我们根据美国食品和药物管理局的重大和极重大错误阈值,评估了这些基因的存在对预测耐药性或敏感性的预测价值。Mash 用于使用 Jaccard 距离计算提取基因之间的相似性。我们根据经验将提取的基因序列重新聚类为 AMR 相关基因家族(匹配度≥70%)和抗生素耐药基因(ARGs;匹配度 100%),并根据其在数据集中的频率进行分类。使用斯皮尔曼系数模拟了牛津郡和其他数据集中的基因频率累积曲线,并计算了两者之间的相关性。使用 Firth 回归法建立 blaTEM-1 变异与阿莫西林-克拉维酸或哌拉西林-他唑巴坦耐药性之间的关联模型,并对其他相关 ARGs 的存在进行调整:AMRFinder 数据库在使用严格的 100%同一性和覆盖率阈值进行基因型对表型预测时,对所评估的七种抗生素中的任何一种都没有达到美国食品药品管理局的阈值。将过滤器放宽到默认设置可提高灵敏度,但特异性要付出代价。对所有抗生素而言,大多数可解释的耐药性都与少量基因的存在有关。已知 ARGs 无法解释的耐药性占一定比例;阿莫西林-克拉维酸为 75-1%,环丙沙星为 3-4%。在检测到的 35 343 个 ARGs 中,只有 18 199 个(51-5%)在 AMRFinder 数据库中具有 100% 的同一性和覆盖率匹配。根据经验对核苷酸序列同一性达到 100% 的基因进行重新分类后,我们发现了 1042 个独特的 ARGs,其中 126 个(12-1%)出现了 10 次或更多次,313 个(30-0%)出现了 2 到 9 次,603 个(57-9%)只出现了一次。模拟积累曲线显示,在数据集中出现一次以上的新 ARGs(100% 匹配)的发现速度相对较快,而新的单个 ARGs 即使在纳入数千个分离物后仍能被发现。我们发现了一种强相关性(斯皮尔曼系数 0-76 [95% CI 0-73-0-80],pTEM-1),表明未编目变异(包括同义变异)与潜在的重要表型差异有关;例如,两个常见的、未编入目录的 blaTEM-1 等位基因只有同义突变,与已知的参照基因相比,与对阿莫西林-克拉维酸(调整后的几率比 0-58 [95% CI 0-35-0-95],p=0-031)和哌拉西林-他唑巴坦(0-50 [95% CI 0-29-0-82],p=0-005)的耐药性降低有关。解释:我们强调了与已知 ARG 相关的大量未编入目录的遗传变异,尽管这些等位基因中相对较小的一部分在一个大型国际数据集中被反复观察到,这表明存在强大的选择压力。目前使用模糊匹配检测 ARG 的方法忽略了未编入目录的变异的未知影响,在未来的临床应用中不太可能被接受。同义突变与潜在的重要表型差异的关联表明,仅仅依靠基于氨基酸的基因检测来预测耐药性是不够的。最后,现有知识无法解释所有抗药性,这凸显了发现新靶基因的重要性:国家健康与护理研究所、惠康公司和英国医学研究委员会。
{"title":"Exploring uncatalogued genetic variation in antimicrobial resistance gene families in Escherichia coli: an observational analysis","authors":"Samuel Lipworth DPhil ,&nbsp;Prof Derrick Crook FRCP ,&nbsp;Prof A Sarah Walker PhD ,&nbsp;Prof Tim Peto FRCP ,&nbsp;Prof Nicole Stoesser DPhil","doi":"10.1016/S2666-5247(24)00152-6","DOIUrl":"10.1016/S2666-5247(24)00152-6","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Antimicrobial resistance (AMR) in &lt;em&gt;Escherichia coli&lt;/em&gt; is a global problem associated with substantial morbidity and mortality. AMR-associated genes are typically annotated based on similarity to variants in a curated reference database, with the implicit assumption that uncatalogued genetic variation within these is phenotypically unimportant. In this study, we evaluated the performance of the AMRFinder tool and, subsequently, the potential for discovering new AMR-associated gene families and characterising variation within existing ones to improve genotype-to-susceptibility phenotype predictions in &lt;em&gt;E coli&lt;/em&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;In this cross-sectional study of international genome sequence data, we assembled a global dataset of 9001 &lt;em&gt;E coli&lt;/em&gt; sequences from five publicly available data collections predominantly deriving from human bloodstream infections from: Norway, Oxfordshire (UK), Thailand, the UK, and Sweden. 8555 of these sequences had linked antibiotic susceptibility data. Raw reads were assembled using Shovill and AMR genes (relevant to amoxicillin–clavulanic acid, ampicillin, ceftriaxone, ciprofloxacin, gentamicin, piperacillin–tazobactam, and trimethoprim) extracted using the National Center for Biotechnology Information AMRFinder tool (using both default and strict [100%] coverage and identity filters). We assessed the predictive value of the presence of these genes for predicting resistance or susceptibility against US Food and Drug Administration thresholds for major and very major errors. Mash was used to calculate the similarity between extracted genes using Jaccard distances. We empirically reclustered extracted gene sequences into AMR-associated gene families (≥70% match) and antibiotic-resistance genes (ARGs; 100% match) and categorised these according to their frequency in the dataset. Accumulation curves were simulated and correlations between gene frequency in the Oxfordshire and other datasets calculated using the Spearman coefficient. Firth regression was used to model the association between the presence of &lt;em&gt;bla&lt;/em&gt;&lt;sub&gt;TEM-1&lt;/sub&gt; variants and amoxicillin–clavulanic acid or piperacillin–tazobactam resistance, adjusted for the presence of other relevant ARGs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;The performance of the AMRFinder database for genotype-to-phenotype predictions using strict 100% identity and coverage thresholds did not meet US Food and Drug Administration thresholds for any of the seven antibiotics evaluated. Relaxing filters to default settings improved sensitivity with a specificity cost. For all antibiotics, most explainable resistance was associated with the presence of a small number of genes. There was a proportion of resistance that could not be explained by known ARGs; this ranged from 75·1% for amoxicillin–clavulanic acid to 3·4% for ciprofloxacin. Only 18 199 (51·5%) of the 35 343 ARGs detected had a 100% identity and coverage mat","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"5 11","pages":"Article 100913"},"PeriodicalIF":20.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme. 接种肺炎球菌结合疫苗对蒙古 2-59 个月住院儿童肺炎球菌携带率的影响:一项积极的肺炎监测计划。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-29 DOI: 10.1016/S2666-5247(24)00171-X
Claire von Mollendorf, Tuya Mungun, Munkhchuluun Ulziibayar, Cattram D Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Belinda D Ortika, Casey L Pell, Ashleigh Wee-Hee, Monica L Nation, Jason Hinds, Eileen M Dunne, E K Mulholland, Catherine Satzke
<p><strong>Background: </strong>Data on changes in pneumococcal serotypes in hospitalised children following the introduction of the pneumococcal conjugate vaccine (PCV) in low-income and middle-income countries are scarce. In 2016, Mongolia introduced the 13-valent PCV (PCV13) into the national immunisation programme. We aimed to describe the trend and impact of PCV13 introduction on pneumococcal carriage in hospitalised children aged 2-59 months with pneumonia in Mongolia over a 6-year period.</p><p><strong>Methods: </strong>In this active surveillance programme, children aged 2-59 months with pneumonia who met the study case definition (cough or difficulty breathing with either respiratory rate ≥50 beats per min, oxygen saturation <90%, or clinical diagnosis of severe pneumonia) were enrolled between April 1, 2015, and June 30, 2021, from four districts in Ulaanbaatar. We tested nasopharyngeal samples collected at enrolment for pneumococci using lytA real-time quantitative PCR and conducted molecular serotyping and detection of antimicrobial resistance (AMR) genes with DNA microarray. We used log-binomial regression to estimate prevalence ratios (PRs) of pneumococcal carriage, comparing prevalence in the periods before and after the introduction of PCV13 and between vaccinated and unvaccinated children for three outcomes: overall, PCV13 vaccine-type, and non-PCV13 vaccine-type carriage. PRs were adjusted with covariates that were identified by use of a directed acyclic graph, informed by relevant literature.</p><p><strong>Findings: </strong>A total of 17 688 children were enrolled, of whom 17 607 (99·5%) met the study case criteria. 6545 (42·5%) of 15 411 collected nasopharyngeal swabs were tested for pneumococci. In all age groups, a similar prevalence of pneumococcal carriage was shown between the pre-PCV13 period and post-PCV13 period (882 [48·0%] of 1837 vs 2174 [46·2%] of 4708; adjusted PR 0·98 [95% CI 0·92-1·04]; p=0·60). Overall, vaccine-type carriage reduced by 43·6% after the introduction of PCV13 (adjusted PR 0·56 [95% CI 0·51-0·62]; p<0·0001). Younger children (aged 2-23 months) showed a 47·7% reduction in vaccine-type carriage (95% CI 41·2-53·5; adjusted PR 0·52 [95% CI 0·46-0·59]; p<0·0001), whereas children aged 24-59 months had a 29·3% reduction (12·6-42·8; 0·71 [0·57-0·87]; p=0·0014). Prevalence of 6A, 6B, 14, 19F, and 23F decreased following the introduction of PCV13; however, 19F and 6A remained common (5·8% and 2·9%). Non-vaccine-type carriage increased (adjusted PR 1·49 [95% CI 1·32-1·67]), with 15A, NT2, and 15B/C being the most prevalent serotypes. Overall, 1761 (89·3%) of 1978 analysed samples contained at least one AMR gene. The percentage of samples with any AMR gene decreased with vaccine introduction (92·3% in the pre-PCV13 period vs 85·3% in the post-PCV13 period; adjusted odds ratio 0·49 [95% CI 0·34-0·70]), with similar decreases for samples with at least three AMR genes (46·8% vs 27·6%; 0·44 [0·36-0·55]).</p><p><
背景:在低收入和中等收入国家引入肺炎球菌结合疫苗 (PCV) 后,住院儿童肺炎球菌血清型变化的数据非常稀少。2016 年,蒙古在国家免疫计划中引入了 13 价 PCV(PCV13)。我们旨在描述 6 年间 PCV13 的引入对蒙古 2-59 个月肺炎住院儿童肺炎球菌携带的趋势和影响:在这项主动监测计划中,符合研究病例定义的 2-59 个月肺炎患儿(咳嗽或呼吸困难,呼吸频率≥50 次/分,血氧饱和度低于 50%)被纳入研究范围:共有 17 688 名儿童报名参加,其中 17 607 名(99-5%)符合研究病例标准。在采集的 15 411 份鼻咽拭子中,有 6545 份(42-5%)进行了肺炎球菌检测。在所有年龄组中,肺炎球菌携带率在接种 PCV13 前和接种 PCV13 后相似(1837 例中的 882 例 [48-0%] vs 4708 例中的 2174 例 [46-2%];调整后 PR 0-98 [95% CI 0-92-1-04];P=0-60)。总体而言,在 PCV13 推出后,疫苗型携带率降低了 43-6%(调整后 PR 为 0-56 [95% CI 0-51-0-62];p 解释:PCV13 推出 6 年后,疫苗型携带率降低了 43-6%(调整后 PR 为 0-56 [95% CI 0-51-0-62]):在蒙古引入 PCV13 6 年后,肺炎住院患儿中疫苗型携带率和 AMR 基因的流行率均有所下降。疫苗型携带的减少很可能会导致肺炎球菌肺炎的减少:资金来源:GAVI、疫苗联盟。
{"title":"Effect of pneumococcal conjugate vaccination on pneumococcal carriage in hospitalised children aged 2-59 months in Mongolia: an active pneumonia surveillance programme.","authors":"Claire von Mollendorf, Tuya Mungun, Munkhchuluun Ulziibayar, Cattram D Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Belinda D Ortika, Casey L Pell, Ashleigh Wee-Hee, Monica L Nation, Jason Hinds, Eileen M Dunne, E K Mulholland, Catherine Satzke","doi":"10.1016/S2666-5247(24)00171-X","DOIUrl":"https://doi.org/10.1016/S2666-5247(24)00171-X","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Data on changes in pneumococcal serotypes in hospitalised children following the introduction of the pneumococcal conjugate vaccine (PCV) in low-income and middle-income countries are scarce. In 2016, Mongolia introduced the 13-valent PCV (PCV13) into the national immunisation programme. We aimed to describe the trend and impact of PCV13 introduction on pneumococcal carriage in hospitalised children aged 2-59 months with pneumonia in Mongolia over a 6-year period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this active surveillance programme, children aged 2-59 months with pneumonia who met the study case definition (cough or difficulty breathing with either respiratory rate ≥50 beats per min, oxygen saturation &lt;90%, or clinical diagnosis of severe pneumonia) were enrolled between April 1, 2015, and June 30, 2021, from four districts in Ulaanbaatar. We tested nasopharyngeal samples collected at enrolment for pneumococci using lytA real-time quantitative PCR and conducted molecular serotyping and detection of antimicrobial resistance (AMR) genes with DNA microarray. We used log-binomial regression to estimate prevalence ratios (PRs) of pneumococcal carriage, comparing prevalence in the periods before and after the introduction of PCV13 and between vaccinated and unvaccinated children for three outcomes: overall, PCV13 vaccine-type, and non-PCV13 vaccine-type carriage. PRs were adjusted with covariates that were identified by use of a directed acyclic graph, informed by relevant literature.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;A total of 17 688 children were enrolled, of whom 17 607 (99·5%) met the study case criteria. 6545 (42·5%) of 15 411 collected nasopharyngeal swabs were tested for pneumococci. In all age groups, a similar prevalence of pneumococcal carriage was shown between the pre-PCV13 period and post-PCV13 period (882 [48·0%] of 1837 vs 2174 [46·2%] of 4708; adjusted PR 0·98 [95% CI 0·92-1·04]; p=0·60). Overall, vaccine-type carriage reduced by 43·6% after the introduction of PCV13 (adjusted PR 0·56 [95% CI 0·51-0·62]; p&lt;0·0001). Younger children (aged 2-23 months) showed a 47·7% reduction in vaccine-type carriage (95% CI 41·2-53·5; adjusted PR 0·52 [95% CI 0·46-0·59]; p&lt;0·0001), whereas children aged 24-59 months had a 29·3% reduction (12·6-42·8; 0·71 [0·57-0·87]; p=0·0014). Prevalence of 6A, 6B, 14, 19F, and 23F decreased following the introduction of PCV13; however, 19F and 6A remained common (5·8% and 2·9%). Non-vaccine-type carriage increased (adjusted PR 1·49 [95% CI 1·32-1·67]), with 15A, NT2, and 15B/C being the most prevalent serotypes. Overall, 1761 (89·3%) of 1978 analysed samples contained at least one AMR gene. The percentage of samples with any AMR gene decreased with vaccine introduction (92·3% in the pre-PCV13 period vs 85·3% in the post-PCV13 period; adjusted odds ratio 0·49 [95% CI 0·34-0·70]), with similar decreases for samples with at least three AMR genes (46·8% vs 27·6%; 0·44 [0·36-0·55]).&lt;/p&gt;&lt;p&gt;&lt;","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"100929"},"PeriodicalIF":20.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Saliva as a reliable, non-invasive specimen for detecting and monitoring Mycobacterium leprae. 唾液是检测和监测麻风分枝杆菌的可靠、无创标本。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-25 DOI: 10.1016/j.lanmic.2024.101014
Xi Yang, Zhengfang Wang, Yuliang Qin, Chiyu Zhang, Yu-Ye Li
{"title":"Saliva as a reliable, non-invasive specimen for detecting and monitoring Mycobacterium leprae.","authors":"Xi Yang, Zhengfang Wang, Yuliang Qin, Chiyu Zhang, Yu-Ye Li","doi":"10.1016/j.lanmic.2024.101014","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101014","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101014"},"PeriodicalIF":20.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood transcriptomic analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19 condition with chronic fatigue syndrome. 血液转录组分析不支持 SARS-CoV-2 在 COVID-19 后慢性疲劳综合征患者中的持续存在。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-25 DOI: 10.1016/j.lanmic.2024.101012
Amirhossein Rahmati, Shima Shahbaz, Mohammed Osman, Jan Willen Cohen Tervaert, Shokrollah Elahi
{"title":"Blood transcriptomic analyses do not support SARS-CoV-2 persistence in patients with post-COVID-19 condition with chronic fatigue syndrome.","authors":"Amirhossein Rahmati, Shima Shahbaz, Mohammed Osman, Jan Willen Cohen Tervaert, Shokrollah Elahi","doi":"10.1016/j.lanmic.2024.101012","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101012","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101012"},"PeriodicalIF":20.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endocarditis associated with contamination of cardiovascular bioprostheses with Mycobacterium chelonae: a collaborative microbiological study. 与心血管生物假体被螯合分枝杆菌污染有关的心内膜炎:一项微生物学合作研究。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-24 DOI: 10.1016/j.lanmic.2024.06.001
Judith Kikhney, Inna Friesen, Solveigh Wiesener, Laura Kursawe, Christoph Loddenkemper, Josef Zündorf, Beate Häuser, Esther P Cónsul Tejero, Dinah V Schöning, Kurosh Sarbandi, Doris Hillemann, Martin Kuhns, Miriam S Stegemann, Frieder Pfäfflin, Frank-Rainer Klefisch, Volker Düsterhöft, Sebastian Haller, Anja V Laer, Tim Eckmanns, Emmanuelle Cambau, Sarah Tschudin-Sutter, Barbara Hasse, Anette Friedrichs, Bernd Panholzer, Walter Eichinger, Petra Gastmeier, Volkmar Falk, Annette Moter

Background: Mycobacterium chelonae is a rare cause of infective endocarditis that is difficult to diagnose and treat. After we found M chelonae in a series of patients, we aimed to investigate its role in cardiovascular prosthesis dysfunction and contamination of bioprostheses as a possible cause of infection.

Methods: In this collaborative microbiological study, we report on nine patients treated in three cardiovascular surgical departments in Germany, who were found to have M chelonae infection after receiving BioIntegral bioprostheses. We performed fluorescence in-situ hybridisation (FISH) combined with broad-range 16S rRNA gene amplification and sequencing (FISHseq) on samples of native cardiovascular tissue and explanted bioprosthetic material, as well as on 12 unused BioIntegral prostheses. We confirmed FISHseq findings with histological examination by staining for acid-fast bacilli, and M chelonae was differentiated from M abscessus by molecular techniques.

Findings: Between Dec 1, 2020, and Feb 28, 2022, we identified M chelonae in BioIntegral bioprostheses from three initial patients treated in Berlin that were explanted following dysfunction or suspected endocarditis, visualising morphologically intact FISH-positive mycobacteria. Despite negative mycobacterial culture, we also detected M chelonae in all 12 unused BioIntegral prostheses. The competent authorities in the EU prompted an alert, leading to the identification of six additional patients between March 1, 2022, and July 31, 2023. To find other cases of M chelonae endocarditis, we reviewed the FISHseq results of 1237 cardiovascular samples that were analysed between Jan 1, 2015, and Aug 31, 2022, including 295 samples from 228 bioprostheses supplied by other manufacturers. M chelonae was only detected in six of 41 patients who had received BioIntegral products.

Interpretation: Bioprostheses manufactured by BioIntegral Surgical might be colonised by M chelonae, which can lead to implant dysfunction. These infections are likely to be missed by conventional routine diagnostics and should be considered in patients with BioIntegral implants and suspected infection or dysfunction. Cases should be reported to public health and regulatory authorities. Routine safety testing of bioprostheses during manufacture should be reconsidered.

Funding: German Federal Ministry of Education and Research.

背景:克氏分枝杆菌是感染性心内膜炎的一种罕见病因,难以诊断和治疗。我们在一系列患者中发现克氏分枝杆菌后,旨在研究其在心血管假体功能障碍中的作用,并将生物假体污染作为可能的感染原因:在这项微生物学合作研究中,我们报告了在德国三个心血管外科部门接受治疗的九名患者的情况,这些患者在接受 BioIntegral 生物假体治疗后发现感染了螯合蘑菇菌。我们对原生心血管组织和取出的生物假体材料样本以及 12 个未使用过的 BioIntegral 假体进行了荧光原位杂交 (FISH) 结合广谱 16S rRNA 基因扩增和测序 (FISHseq)。我们通过对酸性无菌杆菌的染色确认了 FISHseq 的结果,并通过分子技术将 M chelonae 与 M abscessus 区分开来:从 2020 年 12 月 1 日到 2022 年 2 月 28 日,我们在柏林治疗的三位患者的 BioIntegral 生物假体中发现了切诺氏菌,这些患者因功能障碍或疑似心内膜炎而被取出假体,可观察到形态完整的 FISH 阳性分枝杆菌。尽管分枝杆菌培养呈阴性,但我们在所有 12 个未使用的 BioIntegral 假体中都检测到了螯合霉菌。欧盟主管当局发出警报,结果在 2022 年 3 月 1 日至 2023 年 7 月 31 日期间又发现了六名患者。为了找到其他的米氏切诺氏菌心内膜炎病例,我们回顾了2015年1月1日至2022年8月31日期间分析的1237份心血管样本的FISHseq结果,其中包括来自其他制造商提供的228个生物假体的295份样本。在接受过BioIntegral产品治疗的41名患者中,只有6名患者检测到了螯合霉菌:解读:BioIntegral Surgical公司生产的生物假体可能带有螯合霉菌,这会导致假体功能障碍。传统的常规诊断方法很可能会漏诊这些感染,因此在使用 BioIntegral 植入物并怀疑感染或功能障碍的患者中应加以考虑。应向公共卫生和监管机构报告病例。应重新考虑在生产过程中对生物假体进行常规安全检测:德国联邦教育与研究部。
{"title":"Endocarditis associated with contamination of cardiovascular bioprostheses with Mycobacterium chelonae: a collaborative microbiological study.","authors":"Judith Kikhney, Inna Friesen, Solveigh Wiesener, Laura Kursawe, Christoph Loddenkemper, Josef Zündorf, Beate Häuser, Esther P Cónsul Tejero, Dinah V Schöning, Kurosh Sarbandi, Doris Hillemann, Martin Kuhns, Miriam S Stegemann, Frieder Pfäfflin, Frank-Rainer Klefisch, Volker Düsterhöft, Sebastian Haller, Anja V Laer, Tim Eckmanns, Emmanuelle Cambau, Sarah Tschudin-Sutter, Barbara Hasse, Anette Friedrichs, Bernd Panholzer, Walter Eichinger, Petra Gastmeier, Volkmar Falk, Annette Moter","doi":"10.1016/j.lanmic.2024.06.001","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.06.001","url":null,"abstract":"<p><strong>Background: </strong>Mycobacterium chelonae is a rare cause of infective endocarditis that is difficult to diagnose and treat. After we found M chelonae in a series of patients, we aimed to investigate its role in cardiovascular prosthesis dysfunction and contamination of bioprostheses as a possible cause of infection.</p><p><strong>Methods: </strong>In this collaborative microbiological study, we report on nine patients treated in three cardiovascular surgical departments in Germany, who were found to have M chelonae infection after receiving BioIntegral bioprostheses. We performed fluorescence in-situ hybridisation (FISH) combined with broad-range 16S rRNA gene amplification and sequencing (FISHseq) on samples of native cardiovascular tissue and explanted bioprosthetic material, as well as on 12 unused BioIntegral prostheses. We confirmed FISHseq findings with histological examination by staining for acid-fast bacilli, and M chelonae was differentiated from M abscessus by molecular techniques.</p><p><strong>Findings: </strong>Between Dec 1, 2020, and Feb 28, 2022, we identified M chelonae in BioIntegral bioprostheses from three initial patients treated in Berlin that were explanted following dysfunction or suspected endocarditis, visualising morphologically intact FISH-positive mycobacteria. Despite negative mycobacterial culture, we also detected M chelonae in all 12 unused BioIntegral prostheses. The competent authorities in the EU prompted an alert, leading to the identification of six additional patients between March 1, 2022, and July 31, 2023. To find other cases of M chelonae endocarditis, we reviewed the FISHseq results of 1237 cardiovascular samples that were analysed between Jan 1, 2015, and Aug 31, 2022, including 295 samples from 228 bioprostheses supplied by other manufacturers. M chelonae was only detected in six of 41 patients who had received BioIntegral products.</p><p><strong>Interpretation: </strong>Bioprostheses manufactured by BioIntegral Surgical might be colonised by M chelonae, which can lead to implant dysfunction. These infections are likely to be missed by conventional routine diagnostics and should be considered in patients with BioIntegral implants and suspected infection or dysfunction. Cases should be reported to public health and regulatory authorities. Routine safety testing of bioprostheses during manufacture should be reconsidered.</p><p><strong>Funding: </strong>German Federal Ministry of Education and Research.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"100934"},"PeriodicalIF":20.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses. 解决抗生素开发中的当务之急:世界卫生组织 2023 年抗菌药物临床管线分析的启示。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-22 DOI: 10.1016/j.lanmic.2024.100992
Daniela Melchiorri, Tamarie Rocke, Richard A Alm, Alexandra M Cameron, Valeria Gigante

Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.

抗菌药耐药性不断演变,仍然是全球死亡的主要原因之一,5 岁以下儿童的风险最高。解决抗菌药耐药性问题需要采取全面的应对措施,包括感染预防工作、监测、监管、治疗的适宜性和可及性以及研发。然而,抗菌药物的研发工作十分有限,落后于癌症或艾滋病毒研究等其他领域的成果。世卫组织对2023年全球抗菌药物临床管线的分析是监测和指导研发工作的工具。该分析从候选抗菌药物的趋势分析和创新潜力评估中汲取灵感,强调了在开发稳健有效的抗菌药物管线方面仍存在的差距。在本分析中,我们评估了抗生素对 2024 年世卫组织细菌优先病原体新清单的活性,该清单反映了耐药性模式、细菌感染分布和新耐药机制出现的变化趋势。
{"title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.","authors":"Daniela Melchiorri, Tamarie Rocke, Richard A Alm, Alexandra M Cameron, Valeria Gigante","doi":"10.1016/j.lanmic.2024.100992","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.100992","url":null,"abstract":"<p><p>Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.</p>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"100992"},"PeriodicalIF":20.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic epidemiology of Salmonella: the need to consider vaccination history and nutritional status in resistance transmission studies. 沙门氏菌基因组流行病学:在耐药性传播研究中需要考虑疫苗接种史和营养状况。
IF 20.9 1区 生物学 Q1 INFECTIOUS DISEASES Pub Date : 2024-10-22 DOI: 10.1016/j.lanmic.2024.101011
Lianwei Zhou, Minye Wang, Wenbo Li
{"title":"Genomic epidemiology of Salmonella: the need to consider vaccination history and nutritional status in resistance transmission studies.","authors":"Lianwei Zhou, Minye Wang, Wenbo Li","doi":"10.1016/j.lanmic.2024.101011","DOIUrl":"https://doi.org/10.1016/j.lanmic.2024.101011","url":null,"abstract":"","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":" ","pages":"101011"},"PeriodicalIF":20.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Microbe
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1